What’s next in research and development at Novartis (No. 2 on the DiversityInc Top 50 Companies for Diversity list) ? At the company’s annual earnings announcement on January 25, NIBR President Jay Bradner and Head of Global Drug Development Vas Narasimhan shared their outlook on where Novatis will focus its R&D efforts this year, what it means to be a translational drug hunting institute, and why the company insists on a collaborative approach to science. Here are a few highlights from the briefing:
An unprecedented opportunity
In his opening remarks, NIBR president Jay Bradner described how medical science is experiencing a unique moment in its development.
“The convergence of guiding insights into the hardwiring of disease, as well as the recent and radical expansion of the science of therapeutics, creates an unprecedented opportunity to render meaningful contributions to humanity,” said Bradner.
Novartis aims to make the most of this opportunity by bolstering our investment in new tools that support high-quality science in the search for new medicines. For example, we’re using the latest technological advances in DNA barcoding to expand our already massive chemical library, a key departure point for identifying potential new treatments. The goal is to go from 3 million molecules to 300 million in the next three years.